Earnings (Loss) per Common Share
earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number
of common shares outstanding during the period. In periods where there is net income, we apply the two-class method
to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating
security. The two-class method is an earnings allocation formula that treats a participating security as having rights
to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method
of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses.
We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining
whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including
stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the
conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities
would be antidilutive.
Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or
convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive
for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles
for participating securities is not applicable during these periods because those securities do not contractually participate
in its losses.
of December 31, 2018, the Company had 1,165,086 shares of common stock issuable upon the exercise of outstanding options and stock
appreciation rights at a weighted average exercise price of $2.54 per share, 1,131,151 shares of common stock issuable upon the
exercise of outstanding warrants at a weighted average exercise price of $0.70 per share, and 41,743,654 shares of our common
stock issuable upon conversion of our Series A Convertible Preferred Stock. The Company had no unearned restricted shares outstanding
for the period ended December 31, 2018.
accordance with general accounting principles for income taxes, a deferred income tax asset or liability is determined
based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax
rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred income
tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized.
Company’s standard policy is to warrant all systems against defects in material or workmanship for one year following installation.
The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product
performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments
are made to the estimated warranty liability (included in other accrued liabilities) as appropriate.
related to filing and pursuing patent applications are expensed as incurred, as recoverability of such expenditures is uncertain.
majority of the Company’s cash, cash equivalents and investments are deposited with one major financial institution in the
U.S. Deposits in this institution exceed the amount of government provided insurance on such deposits.
from Biosense Webster Inc. related to royalties and Odyssey system sales accounted for $2.9 million and $3.3
million, or 10% and 11%, of total net revenue for the years ended December 31, 2018, and 2017, respectively. No other single
customer accounted for more than 10% of total revenue for the year ended December 31, 2018. No single country other than the U.S.
accounted for more than 10% of total revenue for the years ended December 31, 2018 and 2017.
2018, we adjusted our operating expense categories to improve our alignment with common industry reporting practice, and as a
result, certain amounts in prior periods have been reclassified to conform to the current period presentation. For the year ended
December 31, 2017, approximately $1.9 million of regulatory and clinical research expenses previously included in General and
Administrative expense have been reclassified to Research and Development expense, and approximately $0.6 million of international
training expense previously included in General and Administrative expense has been reclassified to Sales and Marketing expense.
These reclassifications had no effect on reported income or losses.
Issued Accounting Pronouncements
February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2016-02 (“ASU
2016-02”), Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure
of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach,
classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed
purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest
method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use
asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with
a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires
lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct
financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is
effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption
permitted. The Company is substantially complete with our evaluation of the impact of adopting ASU 2016-02 on its consolidated
financial statements and will adopt ASU 2016-02 during the first quarter of 2019 using the alternative modified transition
method. Under this method, the cumulative-effect adjustment to the opening balance of retained earnings is recognized on the date
of adoption with prior periods not restated.